Biotech Evergreen Therapeutics has entered into a clinical service agreement with ICON, a clinical research company, to carry out a global, multi-centre Phase II clinical study of its Covid-19 drug candidate EG-009A. Under the agreement, the randomised, double-blinded controlled trial will be held in Argentina, Brazil and the US, and ICON will manage and oversee the trial and its medical testing responsibilities. The first patients are expected to be enrolled in August 2021, while the trial will be completed by mid-2022.

AstraZeneca has welcomed the ruling by the Court of First Instance in Brussels to supply its Covid-19 vaccine, Vaxzevria, to Europe. The European Commission had requested 120 million doses of the vaccine by the end of June 2021, and a total of 300 million doses by the end of September 2021. The Court ruling ordered the supply of 80.2 million doses of the jab by 27 September 2021. The company has supplied more than 70 million doses of its vaccine to the European Union to date and is expected to exceed 80.2 million doses delivered by the end of June 2021.

The Republic of Korea has pledged to contribute $200m in funding to the Gavi COVAX Advance Market Commitment, an initiative to procure Covid-19 vaccines for 92 low- and middle-income countries globally. Some $100m is expected to be provided in 2021, with an additional $100m to be offered in 2022. The pledge comes along with Korea’s support for COVAX through SKBio, a key supplier of AstraZeneca’s manufacturing network, which has so far delivered 49 million vaccine doses to 85 countries.